Pharmafile Logo

PI3K

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

AZ moves closer to Lynparza filing in breast cancer

PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

- PMLiVE

Novartis signs ‘connected inhaler’ deal with Propeller Health

Will connect its Breezhaler devices to Propeller's digital platform

- PMLiVE

Seattle Genetics signs $2bn deal for Immunomedics’ cancer drug

Buys rights to breast cancer drug candidate that could be be in line for FDA approval by year end

National Institute for Health and Care Excellence NICE logo

NICE set to reject Pfizer’s Ibrance over high cost

Draft guidance on breast cancer therapy calls for more evidence of its benefits

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

Novartis talks the talk with new MS digital tools

Presents real world terms in online dictionary and Chrome Extension

Novartis Gehry Building

Novartis ‘reviewing options’ for Alcon division

Possible sale or spin-off in store for eyecare unit as firm reports Q4 operating loss of $132m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links